SCHEMBL275616

SCHEMBL275616

CCOC(=O)C1CN(C(=O)c2ccc([N+](=O)[O-])cc2)CCc2c1[nH]c1ccccc21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.54
ALDH1A1 P00352 2/20 0.54
POLB P06746 1/20 0.54
KMT2A Q03164 2/20 0.49
TRPV1 Q8NER1 2/20 0.48
FAAH O00519 1/20 0.48
MEN1 O00255 1/20 0.46
ADRA2A P08913 1/20 0.46
ADRA1A P35348 1/20 0.46
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
HTT P42858 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
CDK4 P11802 3/20 0.44
CCND1 P24385 3/20 0.44
NR1H4 Q96RI1 1/20 0.43
MTHFD2 P13995 1/20 0.43
ABCG2 Q9UNQ0 3/20 0.43
ABCB1 P08183 2/20 0.43
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL273558 0.89 ABCG2 (0.52) ALDH1A1ADRA2AADRA1AGAAMAPT
SCHEMBL273349 0.88 ALDH1A1 (0.46) SMN1; SMN2ALDH1A1POLBKMT2AMEN1
SCHEMBL273496 0.88 NR1H4 (0.56) ALDH1A1POLBKMT2AMEN1ADRA2A
SCHEMBL275317 0.88 MAPT (0.51) ALDH1A1ADRA2AADRA1AGAAMAPT
SCHEMBL275525 0.88 ALDH1A1 (0.55) ALDH1A1POLBKMT2AMEN1ADRA2A
SCHEMBL274292 0.87 ABCG2 (0.58) ALDH1A1TRPV1ADRA2AADRA1AGAA
SCHEMBL10290925 0.87 HPGD (0.52) POLBADRA2AADRA1AGAAMAPT
SCHEMBL275183 0.86 TRPV1 (0.47) ALDH1A1KMT2ATRPV1MEN1ADRA2A
SCHEMBL274080 0.81 ALDH1A1 (0.55) SMN1; SMN2ALDH1A1POLBKMT2AMEN1
SCHEMBL275578 0.81 CDK4 (0.56) ALDH1A1KMT2AADRA2AADRA1AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524704-B2 Azepinoindole derivatives as pharmaceutical agents EXELIXIS, INC. (US) 2013-09-03 US disclosed
US-8133992-B2 Azepinoindole and pyridoindole derivatives as pharmaceutical agents EXELIXIS, INC. (US) 2012-03-13 US disclosed
EP-1532153-B1 AZEPINOINDOLE AND PYRIDOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS X CEPTOR THERAPEUTICS INC (US) 2012-02-29 EP disclosed
US-20100173824-A1 Azepinoindole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2010-07-08 US disclosed
US-20090326218-A1 Azepinoindole and Pyridoindole Derivatives as Pharmaceutical Agents EXELIXIS, INC. (US) 2009-12-31 US disclosed
US-7595311-B2 Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents EXELIXIS, INC. (US) 2009-09-29 US disclosed
US-7485634-B2 Azepinoindole and pyridoindole derivatives as pharmaceutical agents EXELIXIS, INC. (US) 2009-02-03 US disclosed
EP-1692136-A2 AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS X-Ceptor Therapeutics, Inc. (US) 2006-08-23 EP disclosed
WO-2005056554-A2 AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2005-06-23 WO disclosed
US-20050054634-A1 Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents AKARNA THERAPEUTICS, LTD. (GB) 2005-03-10 US disclosed
US-20040023947-A1 Azepinoindole and pyridoindole derivatives as pharmaceutical agents X-CEPTOR THERAPEUTICS INC. 2004-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040023947-A1 Azepinoindole and pyridoindole derivatives as pharmaceutical agents HTR5A, MTNR1A, PTGDR SMN1; SMN2 2596/4885ALDH1A1 1722/4885POLB 4706/4885
US-20100173824-A1 Azepinoindole Derivatives As Pharmaceutical Agents HTR2A, HTR5A, HTR2C SMN1; SMN2 2899/4885ALDH1A1 1321/4885POLB 4837/4885
US-20090326218-A1 Azepinoindole and Pyridoindole Derivatives as Pharmaceutical Agents HTR5A, MTNR1A, PTGDR SMN1; SMN2 2596/4885ALDH1A1 1722/4885POLB 4706/4885
US-20050054634-A1 Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents GPR119, IRS1, INSR SMN1; SMN2 2563/4885ALDH1A1 3963/4885POLB 4761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.